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Abstract Cerivastatin is one of the synthetic 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors used for the
treatment and prevention of hypercholesterolaemia. The obser-
vation that patients receiving this drug had a lower incidence at
cancer led to our interest in using it as a putative anticancer
agent. In this study, we tested the cytotoxicity of cerivastatin on
a panel of 5-£uorouracil (5FU) sensitive and resistant cell lines
in vitro. Cerivastatin was cytotoxic to both 5FU sensitive and
resistant cells. Cerivastatin signi¢cantly augmented the cyto-
toxic e¡ect of 5FU on drug sensitive (6^22-fold) and resistant
(229^310-fold) cell lines. Cerivastatin and 5FU acted synergis-
tically. Cerivastatin inhibited nuclear factor UB DNA binding
activity. The enhancing e¡ect of cerivastatin on 5FU was par-
tially mevalonate pathway independent. Cerivastatin may allow
successful 5FU therapy in chemoresistant patients.
1 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
5-Fluorouracil (5FU) has been used for several decades in
the treatment of various solid tumours. 5FU interferes with
DNA synthesis by blocking production of the pyrimidine nu-
cleotide dTMP from dUMP in de novo DNA synthesis,
through inhibition of thymidylate synthase, as well as through
incorporation of £uoro-nucleotides into DNA and RNA [1].
Chemoresistance is still the major obstacle for successful 5FU
chemotherapy. In e¡orts to improve the therapeutic index of
5FU, various 5FU analogues and 5FU combination therapies
have been evaluated [2].
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) re-
ductase catalyses the formation of mevalonate from HMG-
CoA which is a key step in the biosynthesis of cholesterol and
other isoprenes (i.e. mevalonate-derived products) [3]. HMG-
CoA reductase inhibitors (statins) have been widely used for
prevention and treatment of hypercholesterolaemia and ath-
erosclerosis [4]. In recent years, several studies indicate that
statins also inhibit cancer cell growth via a non-lipid related
pathway [5]. Cerivastatin is a synthetic statin. It has been
reported that cerivastatin can induce leukaemia speci¢c apo-
ptosis and inhibit the proliferation of several solid tumour cell
lines [6^8]. More importantly, cerivastatin can improve ther-
apeutic index as it is non-toxic to normal human bone mar-
row progenitors [6]. Cerivastatin also inhibits tumour inva-
siveness and metastasis in vitro [7]. As with other statins,
cerivastatin induced cytotoxicity is mevalonate pathway de-
pendent. Its cytotoxicity can be totally reversed by mevalo-
nate or its derivatives [farnesyl pyrophosphate (FPP) and ger-
anylgeranyl pyrophosphate (GGPP)] [6^8].
Several studies demonstrate that lovastatin enhances the
cytotoxic e¡ect of some anticancer drugs in vitro and in
vivo [9^11]. In this study, we demonstrated that the cytotoxic
e¡ect of 5FU on 5FU sensitive and resistant colorectal cancer
(CRC) cell lines was signi¢cantly enhanced by cerivastatin.
The enhancing e¡ect of cerivastatin on 5FU was partially
mevalonate pathway independent.
2. Materials and methods
2.1. Cell culture and cytotoxicity analysis
Two 5FU resistant (H6305FU and R105FU) and the parent 5FU
sensitive CRC cell lines (H630wt and R10wt) were chosen for this study
(the resistant cell lines were kindly provided by Prof. P.G. Johnston,
The Queen’s University of Belfast, Department of Oncology). Cell
characteristics and culturing conditions have been described previ-
ously [12^14]. The cells (5000/well), cultured overnight in 96-well
£at-bottomed microtitre plates, were exposed to 5FU (Sigma-Aldrich,
Poole, UK), cerivastatin (Bayer, Wuppertal, Germany) or a combina-
tion of both for 96 h and then subjected to a standard 3-[4,5-di-
methylthiazol-2-yl]diphenyltetrazolium bromide (MTT) assay as pre-
viously described [12,15]. For the add-back experiments, mevalonate
(250 WM) was added into the culture. Each experiment was done in
triplicate plates and repeated twice. The IC50 dose of 5FU was calcu-
lated using CalcuSyn software (Biosoft, Cambridge, UK).
2.2. Analysis of the combined e¡ect of 5FU and cerivastatin
Overnight cultured cells (5000/well) were exposed to various con-
centrations of each drug or a combination of these two drugs at a
constant ratio [5FU:cerivastatin = 100:1 (R10wt and R105FU), 168:1
(H6305FU) and 50:1 (H630wt)] with or without mevalonate (250 WM)
for 96 h. The cells were then subjected to MTT analysis as described
above. The combined cytotoxic e¡ect of 5FU with cerivastatin was
determined by CI-isobologram using CalcuSyn software (Biosoft) [16].
Mutually exclusive equations were used to determine the combination
index (CI).
2.3. Electrophoretic mobility shift assays (EMSA)
The cells were cultured in 96-well plates in drug-free medium until
70% con£uent. Cells were then grown in medium containing di¡erent
combinations of 5FU (10 WM), cerivastatin (1 or 3 WM) and meval-
onate (250 WM) for another 24 h. The cells were collected by trypsi-
nisation. Nuclear protein extraction and EMSA were described pre-
viously [17]. Brie£y, equal amounts (5 Wg) of nuclear extract were
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Fig. 1. Cytotoxic e¡ect of cerivastatin with/without mevalonate on 5FU sensitive (A) and resistant (B) CRC cell lines. Cells were cultured in
cerivastatin (ceri, 1^10 WM) with or without mevalonate (mev, 250 WM) for 96 h and subjected to MTT analysis.
Fig. 2. Cerivastatin enhanced cytotoxic e¡ect of 5FU on 5FU sensitive and resistant CRC cell lines. The enhancing e¡ect of cerivastatin was
partially reversed by mevalonate. Cells were cultured in medium containing 5FU (0.1^1000 WM) with or without cerivastatin (0.5 or 1 WM, as
indicated) and mevalonate (250 WM) for 96 h and subjected to MTT analysis. A: R105FU. B: H6305FU. C: H630wt. D: R10wt.
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incubated with 1 Wg poly(dIdC) (Sigma-Aldrich) in binding bu¡er [50
mM Tris (pH 7.6), 250 mM KCl, 25 mM dithiothreitol, 5 M EDTA
and 25% glycerol] for 10 min at room temperature (RT). Approxi-
mately 20 000 cpm of 32P-labelled 22-mer nuclear factor UB (NF-UB)
DNA probe (5P-AGTTGAGGGGACTTTCCCAGGC-3P) was added
and incubated at RT for 20 min. To test binding speci¢city, 5 Wg of
nuclear extract mixture from four cell lines was incubated with 20U
wildtype or mutant (5P-AGTTGATATTACTTTTATAGGC-3P) unla-
belled NF-UB probe for 30 min before EMSA analysis. The complexes
were separated on a 6% polyacrylamide gel and exposed to X-ray ¢lm
for autoradiography.
3. Results
3.1. Cytotoxicity of cerivastatin in CRC cell lines
After 96 h exposure to cerivastatin, the viability of 5FU
sensitive and resistant CRC cell lines was evaluated by
MTT analysis. Cerivastatin alone was toxic to the CRC cell
lines. Fig. 1 demonstrates that cerivastatin was more cytotoxic
to 5FU sensitive cell lines (H630wt IC50 = 0.70 WM, R10wt
IC50 = 1.02 WM) than 5FU resistant cell lines (H6305FU
IC50 = 7.07 WM, R105FU IC50 = 1.75 WM). The cytotoxicity of
cerivastatin was totally reversed by addition of 250 WM me-
valonate which did not a¡ect cell growth when singly used
(data not shown).
3.2. Cerivastatin strongly enhanced 5FU cytotoxicity and
mevalonate partially reversed the e¡ect of cerivastatin
To test the e¡ect of cerivastatin plus 5FU on cell viability,
CRC cell lines were cultured with 5FU (0.1^1000 WM) with or
without cerivastatin (0.5 WM for 5FU sensitive and 1.0 WM for
5FU resistant cell lines) for 96 h before MTT analysis. Fig. 2
and Table 1 demonstrate that the cytotoxic e¡ect of 5FU on
both 5FU sensitive and resistant cell lines was signi¢cantly
enhanced (P6 0.01) by cerivastatin. The enhancing e¡ect of
cerivastatin on 5FU cytotoxicity was signi¢cantly higher in
resistant cell lines (229-fold for H6305FU and 309-fold for
R105FU) than sensitive cell lines (6.2-fold for R10wt and
22.7-fold for H630wt) (Fig. 3). 5FU resistance in drug resistant
cell lines was reversed by addition of cerivastatin (Table 1).
Furthermore, we tested if the enhancing e¡ect of cerivasta-
tin on 5FU was via the mevalonate pathway. Cells were cul-
tured in medium containing mevalonate (250 WM) and ceri-
vastatin (0.5 WM for drug sensitive and 1.0 WM for resistant
cell line) with various concentrations of 5FU. Mevalonate
attenuated but did not completely block the enhancement of
5FU cytotoxicity by cerivastatin in R10wt and R105FU cell
lines (Table 1 and Fig. 3). Even in the presence mevalonate,
cerivastatin still signi¢cantly enhanced the sensitivity of the
cancer cell lines to 5FU (Table 1 and Fig. 3; P6 0.01).
Table 1
IC50 of 5FU tested alone or in combination with cerivastatin and mevalonate
R10wt R105FU H630wt H6305FU
5FU 16.04 (1.68) 477.27 (17.87) 30.85 (4.81) 1106.33 (104.66)
5FU+Ceri 2.64 (0.04)** 1.54 (0.11)** 1.36 (0.07)** 4.83 (0.19)**
5FU+Ceri+Mev 9.97 (0.58)** 58.45 (4.12)** 3.36 (1.01)** 10.39 (0.93)**
Ceri: cerivastatin; Mev: mevalonate; numbers in parentheses: standard errors. **P6 0.01.
Fig. 3. The fold enhanced 5FU cytotoxicity by cerivastatin with/without mevalonate in CRC cell lines. The fold enhancement represents the ra-
tio of IC50 of 5FU in combination with other drugs (as indicated)/IC50 of 5FU used alone. Cerivastatin (ceri) : 0.5 WM for 5FU sensitive and
1.0 WM for 5FU resistant cells ; mevalonate (mev): 250 WM. **P6 0.01.
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3.3. 5FU and cerivastatin had a synergistic cytotoxic e¡ect on
CRC cell lines
CI-isobologram analysis was used to determine if 5FU and
cerivastatin had a synergistic cytotoxic e¡ect on the CRC cell
lines. CIs 1, = 1 and 6 1 indicate antagonistic, additive and
synergistic e¡ects, respectively [16]. Fig. 4 demonstrates that
5FU and cerivastatin had a synergistic cytotoxic e¡ect on the
CRC cell lines in a wide range of cell killing fractions (0.1^
0.9). Although mevalonate (250 WM) slightly increased CI
values in H630wt and R105FU cells when used in combination
with 5FU and cerivastatin, 5FU and cerivastatin still showed
synergistic cytotoxic e¡ect on all four CRC cell lines (Fig. 4).
3.4. Cerivastatin inhibited NF-UB DNA binding activity
Furthermore, we tested if cerivastatin a¡ected the DNA
binding activity of NF-UB, an anti-apoptotic transcription
factor. High NF-UB DNA binding activity was detected
from all but H630wt cells (Fig. 5). 5FU (10 WM) induced the
activity in 5FU sensitive cells further. The high NF-UB activ-
ity in the cells was markedly suppressed by addition of cer-
ivastatin (1 and 3 WM). The inhibiting e¡ect of cerivastatin on
NF-UB DNA binding activity was totally reversed by meval-
onate (250 WM).
4. Discussion
5FU is the ¢rst line drug for chemotherapy of CRC which
is the third leading cancer killer in developed nations [18].
Chemoresistance is the major barrier for successful 5FU che-
motherapy. Use of combination therapies is one of the main
strategies currently being evaluated to overcome chemoresis-
tance [2]. Statins are drugs currently used for hypercholester-
olaemia prevention and treatment. These drugs block the me-
valonate pathway and thereby cholesterol biosynthesis by
inhibiting HMG-CoA reductase. It was reported that cancer
incidence in the patients receiving HMG-CoA reductase in-
hibitor treatment was lower than that in a placebo group [19].
Statins inhibit the proliferation of some leukaemia and solid
tumour cell lines in vitro and spare normal haemopoietic pre-
cursors [6^8,20]. These results underline the feasibility of using
statins as a group of drugs for cancer chemotherapy. In this
study, the cytotoxic e¡ect of cerivastatin, a synthetic HMG-
CoA reductase inhibitor, on a panel of 5FU sensitive and
resistant CRC cell lines was tested. Cerivastatin was cytotoxic
to 5FU sensitive and resistant CRC cell lines in vitro. In
comparison with sensitive cells, 5FU resistant cell lines were
1.7 (R105FU) and 10.1 times (H6305FU) less sensitive to cer-
ivastatin-induced cytotoxicity. The cytotoxic e¡ect of cerivas-
tatin was completely reversed by mevalonate indicating the
e¡ect was induced by HMG-CoA reductase inhibition.
It has been reported that lovastatin augments the cytotoxic
e¡ect of cytosine arabinoside, cisplatin, BCNU and 5FU on
di¡erent human leukaemia and solid cancer cell lines in vitro
and in vivo [9^11]. Furthermore, we tested the e¡ect of 5FU
plus cerivastatin on CRC cell lines. The cytotoxic e¡ect of
5FU on CRC cell lines was signi¢cantly enhanced by addition
of cerivastatin at a low concentration (6 IC30 dose). The che-
moresistance of 5FU resistant cell lines was also reversed by
cerivastatin.
Mevalonate derivatives, FPP and GGPP, are responsible
for Ras and Rho isoprenylation which is a key step in their
membrane translocation and cell signalling [7,21]. Some sta-
tins induce the expression of cyclin dependent kinase inhibi-
tors p21 or p27 which block the cell cycle at the G1 check-
point [22]. A number of studies suggest that blockage of Ras
and Rho isoprenylation and induction of p21/p27 by inhibi-
tion of the mevalonate pathway may play a main role in the
anticancer e¡ect of HMG-CoA reductase inhibitors [7,20^22].
In our study, mevalonate (250 WM, Fig. 2), GGPP (2 WM) or
Fig. 4. CI-isobologram analysis of the combined e¡ect of 5FU and
cerivastatin with or without mevalonate. CI6 1 indicates a synergis-
tic e¡ect.
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FPP (2 WM) (data not shown) can only partially block the
augmentation of 5FU cytotoxicity by cerivastatin. Hence
although the cytotoxic e¡ect of cerivastatin on CRC cell lines
is mevalonate pathway dependent, the enhancing e¡ect of
cerivastatin on 5FU cytotoxicity only partially relies on the
mevalonate pathway. Other molecular mechanisms involved
in the augmentation of cerivastatin to 5FU remain to be elu-
cidated.
NF-UB is a transcription factor which antagonises the cy-
totoxicity of anticancer drugs by inducing the expression of
anti-apoptotic genes (e.g. c-IAPs, IXAP, A1/B£-1 and IEX-IL)
[23^24]. Human cancer cells with induced NF-UB nuclear ac-
tivity have demonstrated resistance to apoptosis induced by
chemotherapy or radiotherapy [25^27]. CRC cell lines resis-
tant to the thymidylate synthase inhibitors, 5FU and ralti-
trexed, demonstrate NF-UB mRNA and protein overexpres-
sion and high NF-UB nuclear activity. Inhibition of NF-UB
activity in CRC cell lines by disul¢ram enhances 5FU cyto-
toxicity and reverses 5FU resistance [28]. Here, we demon-
strated that cerivastatin also inhibited the constitutive and
inducible NF-UB nuclear DNA binding activity. Inhibition
of NF-UB binding activity may be partially responsible for
the anticancer e¡ect of cerivastatin. The NF-UB inhibitory
e¡ect of cerivastatin was mevalonate pathway dependent
and was abolished by addition of mevalonate.
For anti-hypercholesterolaemia purposes, cerivastatin re-
quires to be long-term administered which has caused some
severe side e¡ects [29]. Our study indicates that for anticancer
purposes, cerivastatin may be used in combination with a
5FU containing chemotherapeutic regimen, especially for
CRC patients poorly responsive to 5FU, to increase tumour
cell killing, rather than being used over prolonged periods as
for anti-hypercholesterolaemia treatment. This would mini-
mise the adverse e¡ects related to long-term use of cerivasta-
tin.
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